MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer

V Tisato, R Voltan, A Gonelli, P Secchiero… - Journal of hematology & …, 2017 - Springer
The two murine double minute (MDM) family members MDM2 and MDMX are at the center
of an intense clinical assessment as molecular target for the management of cancer. Indeed …

Waldenström macroglobulinaemia

R Fonseca, S Hayman - British journal of haematology, 2007 - Wiley Online Library
Over time, Waldenström macroglobulinaemia (WM) has evolved conceptually from a clinical
syndrome to a distinct clinicopathological entity. Progress is being made in standardization …

[HTML][HTML] Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia

F Nguyen-Khac, J Lambert, E Chapiro, A Grelier… - …, 2013 - ncbi.nlm.nih.gov
Waldenström's macroglobulinemia is a disease of mature B cells, the genetic basis of which
is poorly understood. Few recurrent chromosomal abnormalities have been reported, and …

TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia

S Poulain, C Roumier, E Bertrand, A Renneville… - Clinical Cancer …, 2017 - AACR
Purpose: TP53 is a tumor-suppressor gene that functions as a regulator influencing cellular
responses to DNA damage, and TP53 alterations are associated with pejorative outcome in …

Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma

WJ Chng, RF Schop, T Price-Troska, I Ghobrial, N Kay… - Blood, 2006 - ashpublications.org
Waldenström macroglobulinemia (WM) is a B-cell malignancy characterized by the ability
of the B-cell clone to differentiate into plasma cells. Although the clinical syndrome and the …

Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management

MA Gertz - American journal of hematology, 2019 - Wiley Online Library
Disease Overview Waldenström macroglobulinemia (WM) is a lymphoplasmacytic
lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include …

6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis

EM Ocio, RFJ Schop, B Gonzalez… - British journal of …, 2007 - Wiley Online Library
Fluorescence in situ hybridisation (FISH) is an effective technique for the cytogenetic
analysis of Waldenström macroglobulinemia (WM), but the potential impact of molecular …

Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management

MA Gertz - American journal of hematology, 2017 - Wiley Online Library
Disease Overview: Waldenström macroglobulinemia (WM) is a lymphoplasmacytic
lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include …

Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management.

MA Gertz - American journal of hematology, 2015 - europepmc.org
Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and
management. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC …

Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management

MA Gertz - American journal of hematology, 2012 - pubmed.ncbi.nlm.nih.gov
Disease overview Waldenström macroglobulinemia (WM) is a lymphoplasmacytic
lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include …